cedazuridine (Inqovi) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
  • InChIKey: VUDZSIYXZUYWSC-DBRKOABJSA-N
  • Mol. Mass: 268.22
  • ALogP: -1.57
  • ChEMBL Molecule:
    cedazuridine  
More Chemistry

Pharmacology

Combination drugs

( decitabine (dacogen), cedazuridine (Inqovi) - other name: decitabine and cedazuridine )

Alternative names

astx727

Organizations (34)

Research & Development (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (1)


 

Myelodysplastic Syndromes (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

BRCA1 Protein (Phase 1)

Breast Neoplasms (Phase 1)

Fusion Proteins, bcr-abl (Phase 2)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2/Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 1/Phase 2)

Melanoma (Phase 1/Phase 2)

Mesothelioma (Phase 2)

Mutation (Phase 1)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 1)

Nerve Sheath Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 1)

Patient Preference (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 50
  • # of Trial Organizations: 34

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue